TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA EXOSOME THERAPEUTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCTS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 SECONDARY SOURCES
2.10 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING PREVALENCE OF LYME DISEASE, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE AND OTHER CHRONIC DEGENERATIVE DISEASES
3.1.2 INCREASING DEMAND FOR ANTI-AGING THERAPY'S
3.2 RESTRAINT
3.2.1 UNMET MEDICAL NEEDS
3.3 OPPORTUNITIES
3.3.1 PROGRESSING THERAPEUTIC VALUE OF EXOSOME
3.3.2 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES
3.3.3 TECHNOLOGICAL ADVANCEMENTS IN EXOSOME
3.3.4 STRATEGIC RESEARCH INITIATIVES BY MARKET PLAYERS
3.3.5 RISING HEALTHCARE INFRASTRUCTURE
3.4 CHALLENGE
3.4.1 LACK OF SKILLED PROFESSIONAL'S REQUIRED FOR THE ISOLATION OF EXOSOME
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 PIPELINE
7 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TYPE
7.1 OVERVIEW
7.2 HYBRID EXOSOMES
7.3 NATURAL EXOSOMES
7.3.1 AUTOLOGOUS EXOSOMES
7.3.2 EXOGENOUS EXOSOMES
8 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY SOURCE
8.1 OVERVIEW
8.2 MESENCHYMAL STEM CELLS
8.3 DENDRITIC CELLS
8.4 BLOOD
8.4.1 B LYMPHOCYTES
8.4.2 OTHERS
8.5 BODY FLUIDS
8.5.1 SYNOVIAL FLUID
8.5.2 AMNIOTIC FLUID
8.5.3 SEMEN
8.5.4 OTHERS
8.6 MILK
8.7 SALIVA
8.8 URINE
8.9 OTHERS
9 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY THERAPY
9.1 OVERVIEW
9.2 CHEMOTHERAPY
9.3 IMMUNOTHERAPY
9.4 GENE THERAPY
10 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY
10.1 OVERVIEW
10.2 BIO MACROMOLECULES
10.2.1 NUCLEIC ACIDS
10.2.2 PEPTIDES
10.2.3 PROTEINS
10.3 SMALL MOLECULES
11 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.2.1 NON-SMALL CELL LUNG CANCER
11.2.2 BREAST CANCER
11.2.3 GASTRIC CANCER
11.2.4 HEAD AND NECK CANCER
11.2.5 OTHERS
11.3 CARDIAC DISORDERS
11.4 METABOLIC DISORDERS
11.5 NEUROLOGY
11.5.1 PARKINSON'S DISEASE
11.5.2 ALZHEIMER'S DISEASE
11.5.3 OTHERS
11.6 BLOOD DISORDERS
11.7 GYNECOLOGY DISORDERS
11.8 INFLAMMATORY DISORDERS
11.9 ORGAN TRANSPLANTATION
11.10 OTHERS
12 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 PARENTERAL
12.3 ORAL
13 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 RESEARCH & ACADEMIC INSTITUTES
13.4 DIAGNOSTIC CENTERS
14 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY GEOGRAPHY
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 MEXICO
?
15 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 COMPANY PROFILE
16.1 STEM CELLS GROUP
16.1.1 COMPANY SNAPSHOT
16.1.2 PRODUCT PORTFOLIO
16.1.3 RECENT DEVELOPMENT
16.2 EXOCOBIO
16.2.1 COMPANY SNAPSHOT
16.2.2 PRODUCT PORTFOLIO
16.2.3 RECENT DEVELOPMENT
16.3 AEGLE THERPEUTICS
16.3.1 COMPANY SNAPSHOT
16.3.2 PIPELINE PORTFOLIO
16.4 AVALON GLOBOCARE CORP.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PIPELINE PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 CAPRICOR THERAPEUTICS
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 CODIAK BIOSCIENCES
16.7.1 COMPANY SNAPSHOT
16.7.2 PIPELINE PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PIPELINE PORTFOLIO
16.8.4 RECENT DEVELOPMENT
?
16.9 EXOPHARM
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PIPELINE PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.10 EVOX THERAPEUTICS
16.10.1 COMPANY SNAPSHOT
16.10.2 PIPELINE PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 JAZZ PHARMACEUTICALS, INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 RENEURON GROUP PLC
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 UNITED THERAPEUTICS CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS